Ciprofloxacin at low levels disrupts colonization resistance of human fecal microflora growing in chemostats

被引:46
作者
Carman, RJ
Simon, MA
Fernández, H
Miller, MA
Bartholomew, MJ
机构
[1] TechLab Inc, Blacksburg, VA 24060 USA
[2] United States Food & Drug Adm, Ctr Vet Med, Rockville, MD 20855 USA
关键词
fluoroquinolone; antimicrobial; antibiotic; residue; nurmi effect; barrier effect; competitive exclusion; intestinal; feces; chemostat;
D O I
10.1016/j.yrtph.2004.08.005
中图分类号
DF [法律]; D9 [法律]; R [医药、卫生];
学科分类号
0301 [法学]; 10 [医学];
摘要
We studied the in vitro effects of a range of ciprofloxacin (CI) concentrations on the human intestinal flora's colonization resistance (CR) to Salmonella kedougou NCTC 12173. Four steady state microbial communities were established in chemostats using inocula from a single pool of human feces. Three chemostats were exposed to CI (0.1, 0.43 and 5 mug/mL, respectively); one served as a no-drug control. The CR of each community was tested by three successive daily challenges of 108 S. kedougou, each delivered in a 1 mL bolus. There was no colonization of the no-drug chemostat. Likewise, after exposure to only 0.1 mug/mL CI there was no loss of CR and S. kedougou did not colonize. Conversely, both the 0.43 and the 5 mug/mL-exposed floras suffered a loss of CR and these chemostats were colonized. S. kedougou overgrew faster and reached higher counts in the presence of 0.43 than it did in the presence of 5 mug/mL. One possible explanation is that CI had a dose-dependent effect on both the challenge strain and CR. Thus, at higher levels, even though CR was disrupted by CI, so too was the growth of the challenge strain. Since exposure to CI elicited a dose-dependent reduction in Escherichia coli counts [Reg. Pharmacol. Toxicol. 33 (2001) 276] our new data suggest that E. coli may contribute to the CR against salmonella. We further conclude that, even at fecal levels below those reached during therapy, CI may impact the human gut flora sufficiently to facilitate colonization by S. kedougou. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:319 / 326
页数:8
相关论文
共 54 条
[1]
Benini A, 1995, MICROECOL T, V25, P46
[2]
PHARMACOKINETICS OF CIPROFLOXACIN AND EFFECT OF REPEATED DOSAGE ON SALIVARY AND FECAL MICROFLORA [J].
BERGAN, T ;
DELIN, C ;
JOHANSEN, S ;
KOLSTAD, IM ;
NORD, CE ;
THORSTEINSSON, SB .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1986, 29 (02) :298-302
[3]
Influence of ciprofloxacin and other antimicrobial drugs on different Escherichia coli strains in continuous-flow cultures under aerobic and anaerobic conditions [J].
Bernhardt, H ;
Schulz, K ;
Zimmermann, K ;
Knoke, M .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (02) :147-152
[4]
Borzio M, 1997, ITAL J GASTROENTEROL, V29, P262
[5]
CIPROFLOXACIN CONCENTRATIONS AND IMPACT OF THE COLON MICROFLORA IN PATIENTS UNDERGOING COLORECTAL SURGERY [J].
BRISMAR, B ;
EDLUND, C ;
MALMBORG, AS ;
NORD, CE .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (03) :481-483
[6]
COMPARISON OF HIGH-PRESSURE LIQUID-CHROMATOGRAPHY AND MICROBIOLOGICAL ASSAY FOR THE DETERMINATION OF BILIARY ELIMINATION OF CIPROFLOXACIN IN HUMANS [J].
BROGARD, JM ;
JEHL, F ;
MONTEIL, H ;
ADLOFF, M ;
BLICKLE, JF ;
LEVY, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1985, 28 (02) :311-314
[7]
CHANGES IN THE PHARMACOKINETICS OF CIPROFLOXACIN AND FECAL FLORA DURING ADMINISTRATION OF A 7-DAY COURSE TO HUMAN VOLUNTEERS [J].
BRUMFITT, W ;
FRANKLIN, I ;
GRADY, D ;
HAMILTONMILLER, JMT ;
ILIFFE, A .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1984, 26 (05) :757-761
[8]
Effects of low levels of ciprofloxacin on a chemostat model of the human colonic microflora [J].
Carman, RJ ;
Woodburn, MA .
REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2001, 33 (03) :276-284
[9]
ORAL CIPROFLOXACIN AND A MONOCLONAL-ANTIBODY TO LIPOPOLYSACCHARIDE PROTECT LEUKOPENIC RATS FROM LETHAL INFECTION WITH PSEUDOMONAS-AERUGINOSA [J].
COLLINS, HH ;
CROSS, AS ;
DOBEK, A ;
OPAL, SM ;
MCCLAIN, JB ;
SADOFF, JC .
JOURNAL OF INFECTIOUS DISEASES, 1989, 159 (06) :1073-1082
[10]
Crabtree TD, 1999, AM SURGEON, V65, P507